These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1383 related items for PubMed ID: 8968657

  • 1. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
    Baumann P.
    Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
    [Abstract] [Full Text] [Related]

  • 2. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.
    Sproule BA, Naranjo CA, Brenmer KE, Hassan PC.
    Clin Pharmacokinet; 1997 Dec; 33(6):454-71. PubMed ID: 9435993
    [Abstract] [Full Text] [Related]

  • 3. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
    Preskorn SH.
    Clin Pharmacokinet; 1997 Dec; 32 Suppl 1():1-21. PubMed ID: 9068931
    [Abstract] [Full Text] [Related]

  • 4. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
    Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K.
    Eur J Clin Pharmacol; 1996 Dec; 51(1):73-8. PubMed ID: 8880055
    [Abstract] [Full Text] [Related]

  • 5. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH, Goa KL.
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of selective serotonin reuptake inhibitors.
    Hiemke C, Härtter S.
    Pharmacol Ther; 2000 Jan; 85(1):11-28. PubMed ID: 10674711
    [Abstract] [Full Text] [Related]

  • 7. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE, Ahern D, Scatina J, Kao J.
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [Abstract] [Full Text] [Related]

  • 8. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
    Baumann P, Rochat B.
    Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 1():15-21. PubMed ID: 7622807
    [Abstract] [Full Text] [Related]

  • 9. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L, Riesenman C, Lam YW.
    Clin Pharmacokinet; 1995 Mar; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [Abstract] [Full Text] [Related]

  • 10. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?
    Rasmussen BB, Brøsen K.
    Ther Drug Monit; 2000 Apr; 22(2):143-54. PubMed ID: 10774624
    [Abstract] [Full Text] [Related]

  • 11. Clinical pharmacokinetics of selective serotonin reuptake inhibitors.
    van Harten J.
    Clin Pharmacokinet; 1993 Mar; 24(3):203-20. PubMed ID: 8384945
    [Abstract] [Full Text] [Related]

  • 12. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.
    Caccia S.
    Clin Pharmacokinet; 1998 Apr; 34(4):281-302. PubMed ID: 9571301
    [Abstract] [Full Text] [Related]

  • 13. Differences in interactions of SSRIs.
    Brøsen K.
    Int Clin Psychopharmacol; 1998 Sep; 13 Suppl 5():S45-7. PubMed ID: 9817620
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.
    von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI.
    J Clin Psychopharmacol; 1995 Apr; 15(2):125-31. PubMed ID: 7782485
    [Abstract] [Full Text] [Related]

  • 15. The pharmacogenetics of the selective serotonin reuptake inhibitors.
    Brøsen K.
    Clin Investig; 1993 Dec; 71(12):1002-9. PubMed ID: 8124052
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic optimisation of therapy with newer antidepressants.
    Goodnick PJ.
    Clin Pharmacokinet; 1994 Oct; 27(4):307-30. PubMed ID: 7834966
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.
    Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE.
    Br J Clin Pharmacol; 1992 Sep; 34(3):262-5. PubMed ID: 1389951
    [Abstract] [Full Text] [Related]

  • 20. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update.
    Hemeryck A, Belpaire FM.
    Curr Drug Metab; 2002 Feb; 3(1):13-37. PubMed ID: 11876575
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.